CD30
5 EU-approved indications of 1 drug need a CD30 result, in 2 tumour types, most of them in hodgkin lymphoma and T-cell lymphoma.
Approved indications5
| Drug | Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|---|
| Hodgkin lymphoma4 | ||||
Adcetris | CD30+ | + doxorubicin, vinblastine and dacarbazine | 1L advanced | None |
Adcetris | CD30+ | + etoposide, cyclophosphamide, doxorubicin, dacarbazine, dexamethasone | 1L advanced | Stage IIB with risk factors, Stage III or Stage IV |
Adcetris | CD30+ | Monotherapy | Consol. | Following autologous stem cell transplant (ASCT); At increased risk of relapse or progression |
Adcetris | CD30+ | Monotherapy | 3L+ | Following ASCT, or following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option |
| T-cell lymphoma1 | ||||
Adcetris | CD30+ | Monotherapy | 2L | Cutaneous T-cell lymphoma only; After at least 1 prior systemic therapy |
CD30 by tumour
Label wording5
The sentence from section 4.1 of the SmPC that each indication above comes from.
- Brentuximab vedotin (Adcetris)
ADCETRIS is indicated for adult patients with previously untreated CD30+ Stage III or IV Hodgkin lymphoma (HL) in combination with doxorubicin, vinblastine and dacarbazine (AVD) (see sections 4.2 and 5.1).
- Brentuximab vedotin (Adcetris)
ADCETRIS is indicated for adult patients with previously untreated CD30+ Stage IIB with risk factors, Stage III or Stage IV HL in combination with etoposide, cyclophosphamide, doxorubicin, dacarbazine, dexamethasone (BrECADD) (see sections 4.2 and 5.1).
- Brentuximab vedotin (Adcetris)
ADCETRIS is indicated for the treatment of adult patients with CD30+ HL at increased risk of relapse or progression following autologous stem cell transplant (ASCT) (see section 5.1).
- Brentuximab vedotin (Adcetris)
ADCETRIS is indicated for the treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL): 1. following ASCT, or 2. following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option.
- Brentuximab vedotin (Adcetris)
ADCETRIS is indicated for the treatment of adult patients with CD30+ cutaneous T-cell lymphoma (CTCL) after at least 1 prior systemic therapy (see section 5.1).